Song, Li
Cohen, David
Ouyang, Zhangyi http://orcid.org/0000-0002-9905-9832
Cao, Yang
Hu, Xihao
Liu, X. Shirley http://orcid.org/0000-0003-4736-7339
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U01CA226196, U24CA224316)
Article History
Received: 18 August 2020
Accepted: 2 April 2021
First Online: 13 May 2021
Competing interests
: X.S.L. is a cofounder, scientific advisory board (SAB) member and consultant of GV20 Oncotherapy and its subsidiaries, SAB memner of 3DMedCare, consultant for Genentech, stockholder of AMGN, JNJ, MRK and PFE and receives sponsored research funding from Takeda and Sanofi. X.H. conducted the work while a postdoctorate fellow at DFCI, and is currently a full-time employee of GV20 Oncotherapy.
Free to read: This content has been made available to all.